Applied Filters
Patent analysis: CRISPR technology in India
It is likely that many patent applications directed to CRISPR technology will be filed in India, says Hemant Singh of Inttl Advocare, who analyses some of the early applications and the rules on patentability.
The world of gene editing patents
CRISPR is only part of the gene editing story, and by studying the patents associated with all of the various methods, a much clearer picture of the entire field can be generated, says Tony Trippe, senior patent analyst for Thomson Reuters.
What the future holds for second medical use patents
Ahead of the English Court of Appeal’s hearing in May in the Warner-Lambert case on second medical use patents, Charlotte Weekes and Tamsin Cornwell of Pinsent Masons examine some of the unanswered questions.
What Canada can learn from SPCs in Europe
Unlike in the EU, Canada does not have additional pharma patent protection to compensate for regulatory delays, but that looks set to change, as Shirley Liang, an IP lawyer in Canada, explains.
Amgen v Sandoz: marketing exclusivity under the BPCIA
The BPCIA requires a biosimilar applicant to notify the reference product sponsor of its drug no later than 180 days before the first commercial marketing date. Darryl Woo, Erin Ator Thomson, Janice Ta and Wendy Wang of Vinson & Elkins report on some of the pressing issues in this area.
Case review: Merck defeated in BMS patent row
In March, Merck unsuccessfully tried to invalidate a patent owned by Bristol-Myers Squibb covering metastatic skin cancer treatment. Ernest Linek of Banner & Witcoff reviews the arguments and the court’s ruling.
The interplay between CRISPR and the Biotech Directive
No patent application directed to CRISPR has yet fallen foul of the EU’s Biotech Directive on the basis of the human embryo use exception, but the technology is still in its nascent stage. Ashley Roughton of Nabarro reports.
The role of healthy sales in IPR
Patent owners and petitioners in the life sciences industry who raise arguments surrounding commercial success during PTAB trials face substantive and procedural roadblocks, argue Christopher Jagoe and James McConnell of Kirkland & Ellis.
Avoiding the Actavis SPC trap
The UK Intellectual Property Office has issued a favourable decision on an SPC for an “innovative” combination product. David Carling and Michael Pears of Potter Clarkson explain the reasoning and examine its implications.
Second medical use patents: why generics are in the dark
Despite several UK court decisions centring on second medical use patents, there are no foolproof ways for generic manufacturers to avoid infringement, as Deborah Hart of Kilburn & Strode explains.
